Osteoarthritis - Preconceptions Damage Awareness and Treatments

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2006-03-29

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Osteoarthritis offers a very attractive commercial target in terms of patient potential, and the explosion in new disease modifying drugs in rheumatoid arthritis has highlighted the possibilities for OA. However, controversy in the Cox-2 class, preconceptions about alternative treatments and even debate around the definition of OA make this a more difficult market to break into than first thought.


Scope

  • Assessment of patient size across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK), including split by age and gender
  • Transcripts based on qualitative interviews with key opinion leaders including physicians, patient advocates and research scientists
  • Investigation of the current unmet needs from a range of professionals involved in osteoarthritis treatment and research
  • Current treatment controversies and novel therapies in the developmental pipeline


    • Report Highlights
    High unmet need and a large patient population are key drivers towards research and innovation in osteoarthritis. Datamonitor estimates that 89 million adults have some form of symptomatic osteoarthritis in the seven major markets. However, ageist perceptions and low awareness provide a substantial negative impact on the market.

    Is a paradigm shift needed in the way osteoarthritis is treated? Treatment currently centers on NSAIDs but in the light of recent controversies demand for alternatives exists. Other effective treatment options are available, not least changing lifestyle factors, but those that are currently available are battling against their own preconceptions.

    Clinical trials for disease modifying and symptomatic products for osteoarthritis require careful design. However, the optimum design is not yet decided among experts. Advances in imaging offer promise, but interpretation of results must be unified and though the identification of biomarkers is progressing, they are often difficult to utilize.


    Reasons to Purchase

  • Identify the challenges in disease modifying clinical trial design including end-point selection
  • Understand the key issues for alternative treatments propelled into the treatment algorithm by the Cox-2 controversies
  • Gain insight into opinion leaders' thoughts on the challenges facing the osteoarthritis market

    • Table of Contents

    Other users found this report page using the following search terms: osteoarthritis arthritis osteoarthritis population awareness osteoarthritis hip 15 31 howard treats symptomatic

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.